Strata Oncology, Inc. Sustainability Profile
Strata Oncology, Inc., a leading player in the precision oncology sector, is headquartered in the United States. Founded in 2012, the company has rapidly established itself as a pioneer in molecular profiling and genomic testing, focusing on advanced cancer diagnostics. Strata's innovative approach centres on its proprietary StrataNGS™ platform, which enables comprehensive genomic analysis to identify actionable mutations in cancer patients, setting it apart in the competitive landscape. With a strong presence across major operational regions in North America, Strata Oncology has achieved significant milestones, including partnerships with prominent healthcare institutions and biopharmaceutical companies. The company’s commitment to improving patient outcomes through personalised medicine has solidified its market position, making it a trusted name in the oncology industry.
DitchCarbon Score
How does Strata Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Strata Oncology, Inc.'s score of 18 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Strata Oncology, Inc.'s reported carbon emissions
Strata Oncology, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Strata Oncology may not have established formal commitments to reduce its carbon footprint or may be in the early stages of developing such initiatives. In the context of the industry, many organisations are increasingly adopting science-based targets and sustainability commitments to address climate change. However, without specific emissions data or reduction initiatives, it is unclear how Strata Oncology aligns with these industry standards. As the company progresses, it may consider implementing strategies to measure and reduce its carbon emissions, thereby contributing to broader climate action efforts.
How Carbon Intensive is Strata Oncology, Inc.'s Industry?
How Carbon Intensive is Strata Oncology, Inc.'s Location?
Strata Oncology, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Strata Oncology, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
